VisionGate
VisionGate offers a non-intrusive lung cancer detection test using advanced AI and 3D imaging technologies, partnering with major institutions like NYU Langone and Kaiser Permanente.
Services
VisionGate offers a non-intrusive lung cancer test that requires only a simple sputum sample. The company provides a take-home test kit, allowing users to collect sputum samples over a three-day period. This service is designed to make cancer detection more accessible and convenient for patients. By eliminating the need for more invasive procedures, VisionGate is improving the patient experience while still providing accurate and reliable results.
Technology
VisionGate utilizes patented AI-powered cancer detection technology and Cell-CT imaging technology to offer high-resolution 3D cell imaging. Their AI-based classification system can analyze 1,000 cell images per second and identify over 800 3D cell features at a 200 nanometer isotropic resolution. These advanced technologies enable VisionGate to detect cancer cells with high precision and efficiency.
Intellectual Property
VisionGate boasts a robust intellectual property portfolio, including over 164 owned patents spanning 12 countries and the European Patent Office. This extensive portfolio reflects VisionGate's commitment to innovation and leadership in the field of cancer detection technology. By securing these patents, the company protects its proprietary technologies and strengthens its competitive position in the market.
Partnerships
VisionGate partners with leading academic and healthcare institutions such as NYU Langone Cancer Center, The Swedish Cancer Institute, and Kaiser Permanente. These partnerships enable the company to collaborate with top experts in the field, enhancing their research and development efforts. This network of prestigious partners helps VisionGate stay at the forefront of lung cancer detection technology and ensures the highest standards of clinical practice.